The <i>JAK2<sub>V617F</sub></i> mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden.

The JAK2_V617F mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden.

Orbell, Lai Yee; Abutheraa, Nouf; Duncombe, Andrew S; McMullin, Mary Frances; Mesa, Ruben; McShane, Charlene M; James, Glen; Anderson, Lesley A.

Afiliación

Orbell LY; School of Medicine, Medical Sciences, and Nutrition University of Aberdeen Aberdeen Scotland UK.
Abutheraa N; School of Medicine, Medical Sciences, and Nutrition University of Aberdeen Aberdeen Scotland UK.
Duncombe AS; Aberdeen Centre for Health Data Science University of Aberdeen Aberdeen Scotland UK.
McMullin MF; University Hospital Southampton NHS Foundation Trust, Southampton England UK.
Mesa R; School of Medicine, Dentistry and Biomedical Sciences Queen's University Belfast Belfast Northern Ireland UK.
McShane CM; Mays Cancer Center at UT Health San Antonio San Antonio Texas USA.
James G; School of Medicine, Dentistry and Biomedical Sciences Queen's University Belfast Belfast Northern Ireland UK.
Anderson LA; Centre for Public Health Queen's University Belfast Belfast Northern Ireland UK.

EJHaem ; 4(4): 1071-1080, 2023 Nov.

Article en En | MEDLINE | ID: mdl-38024634